148 related articles for article (PubMed ID: 34013974)
1. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.
Plander M; Ugocsai P; Seegers S; Orsó E; Reichle A; Schmitz G; Hofstädter F; Brockhoff G
Ann Hematol; 2011 Dec; 90(12):1381-90. PubMed ID: 21465189
[TBL] [Abstract][Full Text] [Related]
3. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
[TBL] [Abstract][Full Text] [Related]
5. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
6. Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.
Thangavadivel S; Zhao Q; Epperla N; Rike L; Mo X; Badawi M; Bystry DM; Phelps MA; Andritsos LA; Rogers KA; Jones J; Woyach JA; Byrd JC; Awan FT
Clin Cancer Res; 2020 Dec; 26(23):6187-6195. PubMed ID: 32958702
[TBL] [Abstract][Full Text] [Related]
7. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
Kriston C; Plander M; Márk Á; Sebestyén A; Bugyik E; Matolcsy A; Barna G
Ann Hematol; 2018 Nov; 97(11):2145-2152. PubMed ID: 29955944
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.
Gehrke I; Gandhirajan RK; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Mol Med; 2011; 17(7-8):619-27. PubMed ID: 21519633
[TBL] [Abstract][Full Text] [Related]
9. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
[TBL] [Abstract][Full Text] [Related]
13. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Aue G; Sun C; Liu D; Park JH; Pittaluga S; Tian X; Lee E; Soto S; Valdez J; Maric I; Stetler-Stevenson M; Yuan C; Nakamura Y; Muranski P; Wiestner A
J Immunol; 2018 Oct; 201(7):1967-1974. PubMed ID: 30104242
[TBL] [Abstract][Full Text] [Related]
14. In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment.
Severin F; Frezzato F; Visentin A; Martini V; Trimarco V; Carraro S; Tibaldi E; Brunati AM; Piazza F; Semenzato G; Facco M; Trentin L
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817171
[TBL] [Abstract][Full Text] [Related]
15. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
Chen CI; Paul H; Snitzler S; Kakar S; Le LW; Wei EN; Lau A; Johnston JB; Gibson SB; Queau M; Spaner D; Croucher D; Sherry B; Trudel S
Leuk Lymphoma; 2019 Apr; 60(4):980-989. PubMed ID: 30277089
[TBL] [Abstract][Full Text] [Related]
18. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
19. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.
Lagneaux L; Delforge A; Dorval C; Bron D; Stryckmans P
Blood; 1993 Oct; 82(8):2379-85. PubMed ID: 7691258
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]